Antibody screening approach could speed development of immune-based cancer treatments
Researchers at Harvard Medical School have developed 'tactical surfaceome profiling' to identify targets for immune-based cancer therapies. This method aims to help immune cells better recognize and destroy lymphoma cells that currently evade treatment.
Why it matters
Advancements in immunotherapy targeting mechanisms could lead to more effective treatments for resistant blood cancers, improving patient outcomes.
by Jacqueline Mitchell, Harvard Medical School
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Schematic representation of the synthesis of conventional bsAbs versus heterodimeric scFv-Fcs bsAbs. Credit: Nature Communications (2026). DOI: 10.1038/s41467-026-76180-5 A team led by Harvard Medical School researchers at Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute has developed a faster way to identify and engineer cancer-fighting therapies.
In a study published in Nature Communications , the team used the new approach to create an investigational treatment that showed strong activity against aggressive B-cell lymphomas in laboratory experiments.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in